Pamela S. Becker, MD, PhD

Pamela S. Becker, MD, PhD

Professor of Medicine
University of Washington
Member, Fred Hutch
Clinical Research Division
Attending Physician
Seattle Cancer Care Alliance


Harvard Medical School, 1986, MD
Harvard Graduate School of Arts and Sciences, 1986, PhD

Research Focus

Dr. Becker is pursuing several areas of translational research investigation, including 1) the mechanism of adhesion mediated chemotherapy resistance in acute myeloid leukemia and 2) hematopoietic stem cell gene therapy for an inherited disorder of DNA repair, Fanconi anemia, 3) application of precision medicine to hematologic malignancies with incorporation of genomic analysis, gene expression analysis, and in vitro high throughput drug sensitivity data to optimize treatment.

Optimizing therapy of hematological malignancies.

  • Environment mediated chemotherapy resistance in acute myeloid leukemia (AML) and multiple myeloma.

    We have performed extensive analysis of the interaction of acute myeloid leukemia or multiple myeloma with the bone marrow microenvironment, focusing on receptors such as VLA-4, CXCR-4 and CD44/E-selectin ligand. We test novel combinations of chemotherapy with agents that disrupt adhesion of leukemia or myeloma cells in the laboratory, that are currently being tested in clinical trials in patients.
  • Precision medicine approaches to acute leukemia, chronic myelogenous leukemia, multiple myeloma and other cancers.

    We have developed an in vitro high throughput drug sensitivity assay for cancer testing and use results from this assay in combination with mutation analysis and gene expression data to choose therapy for patients with refractory or relapsed acute leukemia. We are working to extend this methodology to other cancers.

Gene therapy for inherited stem cell disorders.

  • We performed the preclinical studies with a lentiviral vector in support of a gene therapy clinical trial for Fanconi (aplastic) anemia that is currently open for enrollment.

Clinical trials in acute myeloid leukemia and multiple myeloma.

Clinical Expertise

  • Acute myeloid leukemia
  • Multiple myeloma
  • Bone marrow failure including Aplastic anemia, Myelodysplastic syndrome, and Fanconi anemia
  • Gaucher disease
  • Related blood and bone marrow disorders (e.g.-Waldenstrom’s macroglobulinemia, hairy cell leukemia, acute lymphoblastic and chronic lymphocytic leukemia)

Current Studies

2097 Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)

2521 A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma

7910 Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

9226 Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

UW13037 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

UW14053 A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

UW14070 A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia

UW15075 An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma

Related Labs & Projects

View all labs & projects >
Pamela S. Becker, MD, PhD

Contact Information

(206) 616-1589
(206) 606-6356
Additional contact


(206) 616-1589 (Voicemail)
(206) 288-7234 (Clinic)

Mail Stop:

UW Campus Box 358056